Centessa Pharmaceuticals plc (CNTA)
NASDAQ: CNTA · Real-Time Price · USD
16.63
-0.12 (-0.72%)
At close: Feb 21, 2025, 4:00 PM
16.60
-0.03 (-0.18%)
After-hours: Feb 21, 2025, 7:47 PM EST
Centessa Pharmaceuticals Employees
Centessa Pharmaceuticals had 76 employees as of December 31, 2023. The number of employees decreased by 7 or -8.43% compared to the previous year.
Employees
76
Change (1Y)
-7
Growth (1Y)
-8.43%
Revenue / Employee
$90,171
Profits / Employee
-$2,121,908
Market Cap
2.19B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 76 | -7 | -8.43% |
| Dec 31, 2022 | 83 | -7 | -7.78% |
| Dec 31, 2021 | 90 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
CNTA News
- 6 weeks ago - Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer - GlobeNewsWire
- 2 months ago - Centessa: Shift In Focus With ORX750 Development Continues To Pay Off - Seeking Alpha
- 3 months ago - Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update - GlobeNewsWire
- 5 months ago - Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) - GlobeNewsWire
- 5 months ago - Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares - GlobeNewsWire
- 5 months ago - Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares - GlobeNewsWire
- 5 months ago - Nxera Pharma's Partner Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers - GlobeNewsWire
- 5 months ago - Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers - GlobeNewsWire